Curis, Inc. (NASDAQ:CRIS) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On May 4, 2017, Curis, Inc. announced its financial results for the three month period ended March 31, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On May 2, 2017, James R. McNab, Jr. notified the Board of Directors of Curis, Inc. (the “Company”), that, effective May 16, 2017, he will retire as the Chairman and a member of the Board of Directors. Mr. McNab’s retirement was not due to any disagreement with the Company or its management relating to the Company’s operations, policies or practices.
The Board of Directors approved a modification to Mr. McNab’s vested common stock options such that the exercise period for all such options shall be extended until May 15, 2018, unless such options expire prior to this date.
Mr. McNab was an integral part of Curis’s founding and the Company is grateful for the contributions that Mr. McNab has made during his tenure. The Board and management team join together in thanking Mr. McNab for his many years of leadership and service, and wish him well in all of his endeavors.
Item 9.01. Financial Statements and Exhibits.
(d) The Exhibit to this Current Report on Form 8-K is listed in the Exhibit Index attached hereto.
About Curis, Inc. (NASDAQ:CRIS)
Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer. Curis, Inc. (NASDAQ:CRIS) Recent Trading Information
Curis, Inc. (NASDAQ:CRIS) closed its last trading session down -0.16 at 2.14 with 482,693 shares trading hands.